ACADEMIC AND RESEARCH PEER-REVIEWED MEDICAL JOURNALISSN 1727-2378 (Print)         ISSN 2713-2994 (Online)
Ru
En

Efficacy of Injectable and Oral Formulations of Proton-Pump Inhibitor in Patients with Pancreatitis

27 February 09:20

Study Objective: To compare the efficacy of injectable and oral formulations of pantoprazole, a proton-pump inhibitor, in patients with pancreatitis.

Study Design: This was an open-label, prospective study.

Materials and Methods: This paper describes the results of treatment given in courses to 30 patients with acute pancreatitis or an acute exacerbation of chronic pancreatitis. Of these, 15 patients received pantoprazole 40 mg twice a day as a slow intravenous injection for 5 days followed by oral treatment with the same drug at a dose of 40 mg twice a day for 20 days as part of combination therapy (detoxification, enzyme therapy, and painkillers if needed). The 15-person comparator group received pantoprazole only in tablets at the same dose for 25 days as part of their combination therapy.

Study Results: The study showed that the use of pantoprazole injections resulted in faster pain relief and the disappearance of dyspepsia and provided a greater improvement in pancreatic inflammation (based on ultrasound findings). Moreover, in patients who received injections of pantoprazole, a statistically significant improvement in quality of life, based on VAS assessment, was achieved earlier than in those who received only its tablet formulation.

Conclusion: The use of a new proton-pump inhibitor in two formulations provides new treatment options for patients with acute pancreatitis or an acute exacerbation of chronic pancreatitis.

O. N. Minushkin — Academic and Research Medical Center at the Department of Presidential Affairs of the Russian Federation, Moscow. E-mail: Lemas3@yandex.ru

L. V. Maslovsky — Academic and Research Medical Center at the Department of Presidential Affairs of the Russian Federation, Moscow. E-mail: Lemas3@yandex.ru

A. E. Evsikov — Academic and Research Medical Center at the Department of Presidential Affairs of the Russian Federation, Moscow. E-mail: Lemas3@yandex.ru

O. F. Shaposhnikova — City Clinical Hospital No. 51, Moscow Department of Healthcare. E-mail: Lemas3@yandex.ru

M. S. Makarova — Outpatient Clinic No. 1, Department of Presidential Affairs of the Russian Federation, Moscow. E-mail: Lemas3@yandex.ru

Доктор.ру
27 February 09:20
LITERATURE
  1. Логинов А. Ф. Возможности использования пантопразола в терапии гастроэзофагеальной рефлюксной болезни // Фарматека. 2009. № 13. С. 29–33.
  2. Маев И. В., Кучерявый Ю. А. Желудочное кислотообразование и хронический панкреатит: насколько сильна взаимосвязь? // Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2008. № 3. С. 4–14.
  3. Минушкин О. Н., Максимов В. А. Некоторые спорные вопросы патогенеза и лечения хронического панкреатита // Клин. перспективы гастроэнтерологии, гепатологии. 2007. № 4. С. 25–32.
  4. Симаненков В.И., Кнорринг Г.Ю., Захарова Н.В. Антисекре-торная терапия обострений хронических панкреатитов // Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 1999. Т. 9. № 5. С. 76.
  5. Gedda K., Scott D., Besanson M., Lorentzon P. et al. Turnover of the gastric H+, K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of gastric acid secretion // Gastroenterology. 1995. Vol. 109. N 4. P. 1134–1141.
  6. Johnson А. G., Seidemann P., Рау R. О. NSAID-related adverse drug interactions with clinical relevance. An update // Int. J. Clin. Pharmacol. Ther. 1994. Vol. 32. N 10. P. 509–532.
  7. Katashima M., Yamamoto K., Tokuma Y., Hata T. et al. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans // Eur. J. Drug. Metab. Pharmacokinet. 1998. Vol. 23. N 1. P. 19–26.
  8. Katz P. Review article: putting immediate-release proton-pump inhibitors into clinical practice — improving nocturnal acid control and avoiding the possible complications of excessive acid exposure // Aliment. Pharmacol. Ther. 2005. Vol. 22. Suppl. 3. P. S31–38.
  9. Sachs G. et al. Synthesis or rupture: duration of acid inhibition by proton pump inhibitors // Drugs Today. 2003. Vol. 39. Suppl. A. P. S11–14.
  10. Simon В., Müller P., Bliesath Н., Lühmann R. et al. Single intravenous administration оf the Н+, К(+)-ATPase inhibitor BY 1023/SK&F 96022 — inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man // Aliment. Pharmacol. Ther. 1990. Vol. 4. N 3. P. 239–245.
Новости мировой медицины! Свежие статьи из журнала! Будьте в курсе!

Похожие статьи

Similar article
19 April 00:00, Interview
Interview
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)
19 April 00:00, Paediatrics
A.V. Aksenov, E.A. Ivanovskaya
Successful Use of Tocilizumab in a Child with Systemic Juvenile Idiopathic Arthritis
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)

News